RTP Mobile Logo
Prostate Cancer Update Think Tank Companion CME Activity – Video Module IV: Bone-Directed Therapy
Released February 2011

Dr Matthew R Smith discusses the role of bone health with extended or intermittent androgen deprivation therapy and the efficacy of systemic bone-directed treatments for patients with skeletal metastases.

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, urologists and radiation oncologists.


    • Explain the cumulative risk of osteoporosis, fracture and other skeletal-related complications to patients with prostate cancer receiving long-term continuous or intermittent androgen deprivation therapy, and identify strategies to address these safety concerns.
    • Educate patients with skeletal metastasis about the efficacy of systemic bone-directed treatments, and appraise the role of systemic bone-directed treatments in preventing osteoporotic complications associated with androgen deprivation therapy.
    • Counsel appropriately selected patients about the availability of ongoing clinical trial participation.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains a video component and downloadable slides. The participant should watch the video content.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Matthew R Smith, MD, PhD
    Associate Professor of Medicine
    Harvard Medical School
    Director, Genitourinary Malignancies Program
    Massachusetts General Hospital
    Boston, Massachusetts

    Consulting Agreement: Amgen Inc.

    EDITOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Dendreon Corporation, Millennium Pharmaceuticals Inc and Sanofi-Aventis.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2011
    Expiration date: February 2012

Acknowledge and close

Watch video
(WIFI is recommended for best performance):